Hemotune

Executive Summary

Hemotune is a Swiss biotechnology company pioneering a versatile magnetic nanoparticle platform for selective biomolecule separation from complex fluids. Founded in 2015, the company targets hematology and infectious disease applications, aiming to remove disease triggers directly from the bloodstream with fewer side effects. Its technology has potential in life-saving therapies and advanced biomanufacturing, enabling novel approaches to blood purification and therapeutic extraction. Despite being private with no disclosed funding rounds, the platform's differentiation and broad applicability position it for strategic partnerships and capital raises. Given the early stage, conviction reflects promise tempered by clinical and commercial execution risk.

Upcoming Catalysts (preview)

• 2026-2027Series B or equivalent funding round to advance platform into clinical development70% success
• 2026-2027Partnership with a biopharma or biomanufacturing firm for co-development or licensing60% success
• 2026Publication of preclinical proof-of-concept data in a peer-reviewed journal80% success